Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Sep:1:13.
doi: 10.21037/pcm.2018.09.01. Epub 2018 Sep 18.

AR-V7 and treatment selection in advanced prostate cancer: are we there yet?

Diogo A Bastos  1 , Emmanuel S Antonarakis  2
Affiliations
Comment

AR-V7 and treatment selection in advanced prostate cancer: are we there yet?

Diogo A Bastos et al. Precis Cancer Med. 2018 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: ES Antonarakis has served as a paid consultant/advisor for Janssen, Astellas, Sanofi, Dendreon, Merck, Essa, and Medivation; has received research funding to his institution from Janssen, Johnson & Johnson, Medivation, Sanofi, Dendreon, Bristol Myers Squibb, Genentech, Novartis, Bayer and Tokai; and is a co-inventor of an AR-V7 biomarker technology that has been licensed to Qiagen. DA Bastos has served as a paid consultant/advisor for Janssen, Astellas, Sanofi, Merck, and Roche; and has received research funding to his institution from Janssen.

Comment on

References

    1. Sartor O, de Bono JS. Metastatic Prostate Cancer. N Engl J Med 2018;378:645–57. - PubMed
    1. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N EnglJ Med 2014;371:1028–38. - PMC - PubMed
    1. Antonarakis ES, Lu C, Luber B, et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol 2015;1:582–91. - PMC - PubMed
    1. Antonarakis ES, Lu C, Luber B, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149–56. - PMC - PubMed
    1. Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol 2016;2:1441–9. - PMC - PubMed

LinkOut - more resources